M&A Deal Summary |
|
|---|---|
| Date | 2011-03-01 |
| Target | King Pharmaceuticals |
| Sector | Life Science |
| Buyer(s) | Pfizer |
| Deal Type | Add-on Acquisition |
| Deal Value | 3.6B USD |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1849 |
| Sector | Life Science |
| Employees | 81,000 |
| Revenue | 63.6B USD (2024) |
Pfizer is a global pharmaceutical company that is involved in the discovery, development, manufacture, and marketing of a wide range of healthcare products, including medicines and vaccines. The company's portfolio includes treatments across a broad spectrum of areas such as oncology, cardiology, neurology, and infectious diseases, among others. Pfizer was founded in 1849 and is based in New York, New York.
| DEAL STATS | # |
|---|---|
| Overall | 15 of 46 |
| Sector: Life Science M&A | 13 of 41 |
| Type: Add-on Acquisition M&A Deals | 13 of 33 |
| State: Tennessee M&A | 1 of 1 |
| Country: United States M&A | 13 of 33 |
| Year: 2011 M&A | 2 of 5 |
| Size (of disclosed) | 13 of 24 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2011-02-07 |
Ferrosan A/S
Soeborg, Denmark Ferrosan Consumer Health is engaged in the sale of science-based consumer healthcare products primarily in the Nordic region and the emerging markets of Russia and Central and Eastern Europe. Ferrosan Consumer Health offers a focused product portfolio of well-established brands including Multi-tabs®, the reference product in the multivitamin segment in the Nordic region, Bifiform®, a market-leading fast growing probiotics product range, Fri Flyt/Active Omega-3, a premium product range addressing the omega-3 market for heart and joint health, and IMEDEEN®, the global leader within oral skin care. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2011-04-04 |
Capsugel Belgium NV
Colmar, France Capsugel Belgium NV is a provider of hard capsules and an innovator in drug delivery systems for the pharmaceutical, OTC and health and nutrition industries. Capsugel offers a comprehensive array of products and services, from hard gelatin, vegetarian and liquid-filled capsules, to innovative R&D equipment and liquid formulations as part of its Licaps Drug Delivery System. |
Sell | $2.4B |